Anika Therapeutics Statistics
Share Statistics
Anika Therapeutics has 14.65M shares outstanding. The number of shares has increased by 0.03% in one year.
| Shares Outstanding | 14.65M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -1.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 14.13M |
| Failed to Deliver (FTD) Shares | 76 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 380.35K, so 2.6% of the outstanding shares have been sold short.
| Short Interest | 380.35K |
| Short % of Shares Out | 2.6% |
| Short % of Float | 2.69% |
| Short Ratio (days to cover) | 3.65 |
Valuation Ratios
The PE ratio is -4.02 and the forward PE ratio is -84.4.
| PE Ratio | -4.02 |
| Forward PE | -84.4 |
| PS Ratio | 1.99 |
| Forward PS | 1.8 |
| PB Ratio | 1.56 |
| P/FCF Ratio | -46.03 |
| PEG Ratio | n/a |
Enterprise Valuation
Anika Therapeutics Inc. has an Enterprise Value (EV) of 288.27M.
| EV / Earnings | -3.49 |
| EV / Sales | 1.73 |
| EV / EBITDA | -25.67 |
| EV / EBIT | -3.29 |
| EV / FCF | -39.95 |
Financial Position
The company has a current ratio of 5.26, with a Debt / Equity ratio of 0.14.
| Current Ratio | 5.26 |
| Quick Ratio | 3.76 |
| Debt / Equity | 0.14 |
| Total Debt / Capitalization | 12.03 |
| Cash Flow / Debt | -0.06 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.39% and return on capital (ROIC) is -35.19%.
| Return on Equity (ROE) | -0.39% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -35.19% |
| Revenue Per Employee | 466.84K |
| Profits Per Employee | -231.56K |
| Employee Count | 357 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.37 |
Taxes
| Income Tax | -2.66M |
| Effective Tax Rate | 0.03 |
Stock Price Statistics
The stock price has increased by -28.97% in the last 52 weeks. The beta is 0.86, so Anika Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | -28.97% |
| 50-Day Moving Average | 16.85 |
| 200-Day Moving Average | 23.53 |
| Relative Strength Index (RSI) | 35.38 |
| Average Volume (20 Days) | 101.69K |
Income Statement
In the last 12 months, Anika Therapeutics had revenue of 166.66M and earned -82.67M in profits. Earnings per share was -5.64.
| Revenue | 166.66M |
| Gross Profit | 103.09M |
| Operating Income | -87.64M |
| Net Income | -82.67M |
| EBITDA | -11.23M |
| EBIT | -87.64M |
| Earnings Per Share (EPS) | -5.64 |
Balance Sheet
The company has 72.87M in cash and 29.04M in debt, giving a net cash position of 43.83M.
| Cash & Cash Equivalents | 72.87M |
| Total Debt | 29.04M |
| Net Cash | 43.83M |
| Retained Earnings | 128.05M |
| Total Assets | 231.41M |
| Working Capital | 110.61M |
Cash Flow
In the last 12 months, operating cash flow was -1.79M and capital expenditures -5.43M, giving a free cash flow of -7.21M.
| Operating Cash Flow | -1.79M |
| Capital Expenditures | -5.43M |
| Free Cash Flow | -7.21M |
| FCF Per Share | -0.49 |
Margins
Gross margin is 61.85%, with operating and profit margins of -52.58% and -49.6%.
| Gross Margin | 61.85% |
| Operating Margin | -52.58% |
| Pretax Margin | -51.2% |
| Profit Margin | -49.6% |
| EBITDA Margin | -6.74% |
| EBIT Margin | -52.58% |
| FCF Margin | -4.33% |
Dividends & Yields
ANIK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -36.18% |
| FCF Yield | -3.16% |
Analyst Forecast
The average price target for ANIK is $24.5, which is 57.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $24.5 |
| Price Target Difference | 57.2% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 4.08 |
| Piotroski F-Score | 3 |